Search Clinical Trials
596,361 trials
ID
Status
Phase
Title
Sponsor
NCT07738562
Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmacokinetics, and Biological EffectsHadassah Medical OrganizationNot Yet RecruitingPhase 1
NCT07738562Not Yet Recruiting
Phase 1
Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmac...Hadassah Medical Organiza...
NCT07739446
Randomized Controlled Trial to Evaluate the Efficacy of Surgical Masks in Preventing Acute Respiratory InfectionsChiba UniversityEnrolling By InvitationNot Applicable
NCT07739446Enrolling By Invitation
Not Applicable
Randomized Controlled Trial to Evaluate the Efficacy of Surgical Masks in Preven...Chiba University
NCT07738536
Ketosis, Immune Function and Metabolic Adaptation in Response to Short-term Fasting in Critical IllnessKarolinska University HospitalNot Yet RecruitingNot Applicable
NCT07738536Not Yet Recruiting
Not Applicable
Ketosis, Immune Function and Metabolic Adaptation in Response to Short-term Fast...Karolinska University Hos...
NCT07739797
A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System ProductsRAI Services CompanyNot Yet RecruitingNot Applicable
NCT07739797Not Yet Recruiting
Not Applicable
A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System Produ...RAI Services Company
NCT07740655
Low-dose Versus Standard-dose Remimazolam for Prevention of Emergence Agitation After Nasal SurgeryJeju National University School of MedicineNot Yet RecruitingPhase 4
NCT07740655Not Yet Recruiting
Phase 4
Low-dose Versus Standard-dose Remimazolam for Prevention of Emergence Agitation...Jeju National University...
NCT07740044
Medical Large Language Model-Assisted Diagnosis and Treatment in Primary Care Chronic Disease ManagementJiangsu Taizhou People's HospitalNot Yet RecruitingNot Applicable
NCT07740044Not Yet Recruiting
Not Applicable
Medical Large Language Model-Assisted Diagnosis and Treatment in Primary Care Ch...Jiangsu Taizhou People's...
NCT07738445
Retreat-Based Program for Violence-Exposed Women VeteransVA Office of Research and DevelopmentNot Yet RecruitingPhase 2
NCT07738445Not Yet Recruiting
Phase 2
Retreat-Based Program for Violence-Exposed Women VeteransVA Office of Research and...
NCT07740538
Malnutrition and Sarcopenia Among Primary Ciliary DyskinesiaIzmir Democracy UniversityNot Yet Recruiting
NCT07740538Not Yet Recruiting
—
Malnutrition and Sarcopenia Among Primary Ciliary DyskinesiaIzmir Democracy Universit...
NCT07739628
Validation of a Deep Learning Tool for Opportunistic Osteoporosis Screening Using Routine Non-Contrast CT ScansUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEnrolling By Invitation
NCT07739628Enrolling By Invitation
—
Validation of a Deep Learning Tool for Opportunistic Osteoporosis Screening Usin...Union Hospital, Tongji Me...
NCT07739914
Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)Hannover Medical SchoolNot Yet RecruitingPhase 3
NCT07739914Not Yet Recruiting
Phase 3
Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIv...Hannover Medical School
NCT07738601
Patient Reported Outcome Measurement Within the Secured Access to Innovative Medicines for Children With cAncer (SACHA) StudyAssistance Publique Hopitaux De MarseilleNot Yet Recruiting
NCT07738601Not Yet Recruiting
—
Patient Reported Outcome Measurement Within the Secured Access to Innovative Med...Assistance Publique Hopit...
NCT07738575
Same-Day Versus Standard Hospital Discharge After TAVI (HOME-TAVI)Hospital Clinic of BarcelonaNot Yet RecruitingNot Applicable
NCT07738575Not Yet Recruiting
Not Applicable
Same-Day Versus Standard Hospital Discharge After TAVI (HOME-TAVI)Hospital Clinic of Barcel...
NCT07739160
The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke PatientsBeijing Suncadia Pharmaceuticals Co., LtdNot Yet RecruitingPhase 2
NCT07739160Not Yet Recruiting
Phase 2
The Efficacy and Safety of HRS-4029 in Acute Ischemic Stroke PatientsBeijing Suncadia Pharmace...
NCT07740512
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol)Polaryx Therapeutics, Inc.Not Yet RecruitingPhase 2
NCT07740512Not Yet Recruiting
Phase 2
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in P...Polaryx Therapeutics, Inc...
NCT07740317
Neurocognitive Trajectories After BCMA CAR-TAtrium Health Wake Forest BaptistNot Yet Recruiting
NCT07740317Not Yet Recruiting
—
Neurocognitive Trajectories After BCMA CAR-TAtrium Health Wake Forest...
NCT07740395
Connecting Loved Ones to Support and Empowering RecoveryRhode Island HospitalRecruitingNot Applicable
NCT07740395Recruiting
Not Applicable
Connecting Loved Ones to Support and Empowering RecoveryRhode Island Hospital
NCT07739043
NeuroRise: Intrathecal CE-1 Treatment for Traumatic SCICell Therapy LLCNot Yet RecruitingEarly Phase 1
NCT07739043Not Yet Recruiting
Early Phase 1
NeuroRise: Intrathecal CE-1 Treatment for Traumatic SCICell Therapy LLC
NCT07739069
Action Observation Versus Mirror Therapy in Children With Spastic Hemiplegic Cerebral PalsyCairo UniversityNot Yet RecruitingNot Applicable
NCT07739069Not Yet Recruiting
Not Applicable
Action Observation Versus Mirror Therapy in Children With Spastic Hemiplegic Cer...Cairo University
NCT07739472
Mobile Application-Supported Education in Nursing StudentsMaltepe UniversityCompletedNot Applicable
NCT07739472Completed
Not Applicable
Mobile Application-Supported Education in Nursing StudentsMaltepe University
NCT07739537
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesMassachusetts General HospitalNot Yet RecruitingPhase 4
NCT07739537Not Yet Recruiting
Phase 4
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesMassachusetts General Hos...
Result Breakdown
Not yet recruiting16 (80%)
Enrolling by invitation2 (10%)
Recruiting1 (5%)
Completed1 (5%)
not_applicable8 (40%)
Not Specified4 (20%)
Phase 23 (15%)
Phase 42 (10%)
Phase 11 (5%)
Phase 31 (5%)
Early Phase 11 (5%)